Real-world clinical outcomes of patients (Pts) with metastatic colorectal cancer (mCRC) who received trifluridine-tipiracil (FTD-TPI) monotherapy or FTD-TPI plus bevacizumab (FTD-TPI plus bev) combination therapy.

被引：0
|
作者：
Nusrat, Maliha
Zhao, Ruizhi
Khan, Nadeem
Wang, Yuexi
Pierre-Victor, Dudith
Tepsick, Jon G.
Sharath, R.
Cann, Christopher G.
Salimi, Tehseen
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Taiho Oncol Inc, Princeton, NJ USA
[3] ConcertAI LLC, Cambridge, MA USA
[4] Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.79
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：79 / 79
页数：1
相关论文
共 45 条
  • [31] Trifluridine/tipiracil (FTD/TPI) in extensively pre-treated metastatic colorectal cancer (mCRC) patients: Evaluation of prognostic subgroups of the TALLISUR study
    Karthaus, Meinolf
    Weiss, Lena
    Riera-Knorrenschild, Jorge
    Kretzschmar, Albrecht
    Welslau, Manfred
    Vehling-Kaiser, Ursula
    Pelz, Henning
    Ettrich, Thomas Jens
    Held, Swantje
    Kehrmann, Linde
    Hess, Juergen
    Reislaender, Timo
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Two Cases of Long-Term Control of Metastatic Colorectal Cancer via FTD/TPI plus Bevacizumab in Elderly Patients
    Shibutani, Masatsune
    Maeda, Kiyoshi
    Nagahara, Hisashi
    Fukuoka, Tatsunari
    Iseki, Yasuhito
    Matsutani, Shinji
    Wang, En
    Hirakawa, Kosei
    Ohira, Masaichi
    CASE REPORTS IN ONCOLOGY, 2018, 11 (03): : 800 - 805
  • [33] Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study
    Taieb, J.
    Falcone, A.
    Lonardi, S.
    Price, T. J.
    Bachet, J-B.
    Wyrwicz, L.
    Ciardiello, F.
    Becquart, M.
    Mounedji, N.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 155 - 155
  • [34] Pooled safety analysis from phase 3 studies of trifluridine/tipiracil (FTD/TPI) in patients (pts) with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC) and metastatic colorectal cancer (mCRC).
    Van Cutsem, Eric
    Hochster, Howard S.
    Shitara, Kohei
    Mayer, Robert J.
    Ohtsu, Atsushi
    Falcone, Alfredo
    Yoshino, Takayuki
    Doi, Toshihiko
    Ilson, David H.
    Arkenau, Hendrik-Tobias
    George, Ben
    McGuigan, Sandra
    Makris, Lukas
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [35] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Gianluca Arrichiello
    Alessandra Perrone
    Stefania Napolitano
    Giulia Martini
    Vincenzo De Falco
    Pasquale Incoronato
    Maria Maddalena Laterza
    Gaetano Facchini
    Vincenzo Famiglietti
    Valeria Nacca
    Fernando Paragliola
    Rossella Napolitano
    Gabriella Suarato
    Antonella Nicastro
    Erika Martinelli
    Davide Ciardiello
    Fortunato Ciardiello
    Teresa Troiani
    Targeted Oncology, 2022, 17 : 635 - 642
  • [36] Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
    Arrichiello, Gianluca
    Perrone, Alessandra
    Napolitano, Stefania
    Martini, Giulia
    De Falco, Vincenzo
    Incoronato, Pasquale
    Laterza, Maria Maddalena
    Facchini, Gaetano
    Famiglietti, Vincenzo
    Nacca, Valeria
    Paragliola, Fernando
    Napolitano, Rossella
    Suarato, Gabriella
    Nicastro, Antonella
    Martinelli, Erika
    Ciardiello, Davide
    Ciardiello, Fortunato
    Troiani, Teresa
    TARGETED ONCOLOGY, 2022, 17 (06) : 635 - 642
  • [37] Prospective, multicenter, open-label, double-arm trial of Trifluridine/Tipiracil (FTD/TPI) to evaluate the Health-related Quality of Life (HRQoL) in patients with Metastatic Colorectal Cancer (mCRC)
    Karthaus, M.
    Kretzschmar, A.
    Fuxius, S.
    Riera-Knorrenschild, J.
    Vehling-Kaiser, U.
    Mahlberg, R.
    Welslau, M.
    Pelz, H.
    Heinemann, V
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 287 - 287
  • [38] Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
    Komatsu, Yoshito
    Kato, Takeshi
    Kagawa, Yoshinori
    Yoshino, Takayuki
    Kuboki, Yasutoshi
    Gamoh, Makio
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Satake, Hironaga
    Goto, Masahiro
    Tanioka, Hiroaki
    Oki, Eiji
    Kotaka, Masahito
    Makiyama, Akitaka
    Denda, Tadamichi
    Soeda, Junpei
    Shibuya, Kazunori
    Iwata, Masaru
    Oba, Koji
    Yamaguchi, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [39] Impact of KRAS codon-specific mutations on survival of patients with metastatic CRC (mCRC) treated with trifluridine-tipiracil (TAS) plus bevacizumab (Bev): A real-world analysis
    Maddalena, Giulia
    van der Pol, Ymke
    Rivers, Zachary
    Dasari, Arvind
    Rogers, Jane E.
    Guinney, Justin
    Kopetz, Scott
    Raghav, Kanwal Pratap Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 201 - 201
  • [40] COST-EFFECTIVENESS OF TRIFLURIDINE/TIPIRACIL (FTD/TPI) AS A THIRD-LINE TREATMENT OF METASTATIC GASTRIC CANCER, INCLUDING ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION, AMONG PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES FOR METASTATIC DISEASE IN GREECE
    Gourzoulidis, G.
    Koulentaki, M.
    Koumarianou, A.
    Samantas, E.
    Androulakis, N.
    Xynogalos, S.
    Papakotoulas, P.
    Boukovinas, I
    Karamouzis, M.
    Souglakos, I
    Chotzagiannoglou, V
    Beletsi, A.
    Kourlaba, G.
    VALUE IN HEALTH, 2020, 23 : S439 - S439
12345